As­traZeneca dumps off a mid-stage PAD hope­ful, sound­ing re­treat from a packed mar­ket

Car­dio­vas­cu­lar dis­ease is hav­ing some­what of a re­vival in re­cent years, with a spate of next-gen­er­a­tion heart drugs crack­ing open ma­jor in­di­ca­tions. But for at least one drug’s R&D jour­ney, As­traZeneca has de­cid­ed to give up the reins rather than ride it out.

As­traZeneca has grant­ed ex­clu­sive de­vel­op­ment and com­mer­cial rights to Re­gio Bio­sciences for REG-101, a car­dio­vas­cu­lar drug ex­pect­ed to en­ter Phase IIa tri­als for pe­riph­er­al artery dis­ease (PAD) in the sec­ond half, the com­pa­nies said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER